Internal Medicine C, Emek Medical Center, Afula, Israel.
Heart Institute, Emek Medical Center, Afula, Israel.
PLoS One. 2020 Aug 7;15(8):e0237024. doi: 10.1371/journal.pone.0237024. eCollection 2020.
Thrombin, a key enzyme of the clotting system, is involved in thrombus formation, platelet activation, and atherosclerosis, thereby possessing a central role in the pathogenesis of ischemic heart disease. Studies have shown an association between thrombin generation (TG) and cardiovascular morbidity and mortality, but results have been equivocal. Our aim was to study the predictive ability of TG assay in evaluating coronary stenosis severity.
In this prospective study we recruited patients with acute coronary syndrome (ACS) or acute chest pain (without evidence of myocardial injury) planned for coronary angiography. Thrombin generation was evaluated by Calibrated Automated Thrombogram (CAT) prior to angiography. Primary end points were significant coronary stenosis and the Syntax I score evaluated by coronary angiography.
From April 2018 through September 2019, we recruited 128 patients. In the primary analysis there was no significant association between TG and significant coronary stenosis nor between TG and syntax I score, however, there was a positive correlation between peak height and troponin peak (Spearman correlation coefficient 0.194, P-value = 0.035). In sub-group analysis, the chest pain group bare no association between TG and coronary stenosis. In unstable angina group there was an association between peak height and significant coronary stenosis (P-value = 0.029), and in non ST-elevation myocardial infarction group, TG values possessed a relatively good predictive ability of significant coronary stenosis (area under the receiver operating characteristic curve of ~65%) and a positive correlation between both lag time and ttpeak with the syntax I score was noticed (Spearman correlation coefficient 0.31, P-value = 0.099 and Spearman correlation coefficient 0.37, P-value = 0.045 respectively).
In patients with acute chest pain, TG values, evaluated by CAT, do not predict severity of coronary stenosis, nor do they possess prognostic value. Yet, in ACS patients, TG may have the ability to predict coronary disease severity.
凝血酶是凝血系统的关键酶,参与血栓形成、血小板激活和动脉粥样硬化,因此在缺血性心脏病的发病机制中起核心作用。研究表明,凝血酶生成(TG)与心血管发病率和死亡率之间存在关联,但结果存在争议。我们的目的是研究 TG 测定在评估冠状动脉狭窄严重程度中的预测能力。
在这项前瞻性研究中,我们招募了计划接受冠状动脉造影的急性冠状动脉综合征(ACS)或急性胸痛(无心肌损伤证据)患者。在进行血管造影前,通过 Calibrated Automated Thrombogram(CAT)评估凝血酶生成。主要终点是由冠状动脉造影评估的显著冠状动脉狭窄和 Syntax I 评分。
从 2018 年 4 月至 2019 年 9 月,我们招募了 128 名患者。在主要分析中,TG 与显著冠状动脉狭窄之间以及 TG 与 syntax I 评分之间均无显著相关性,但峰高与肌钙蛋白峰之间呈正相关(Spearman 相关系数 0.194,P 值=0.035)。在亚组分析中,胸痛组 TG 与冠状动脉狭窄之间无关联。在不稳定型心绞痛组中,峰高与显著冠状动脉狭窄之间存在关联(P 值=0.029),在非 ST 段抬高型心肌梗死组中,TG 值对显著冠状动脉狭窄具有较好的预测能力(接受者操作特征曲线下面积约为 65%),并且发现滞后时间和 ttpeak 与 syntax I 评分之间存在正相关(Spearman 相关系数 0.31,P 值=0.099 和 Spearman 相关系数 0.37,P 值=0.045)。
在急性胸痛患者中,通过 CAT 评估的 TG 值不能预测冠状动脉狭窄的严重程度,也没有预后价值。然而,在 ACS 患者中,TG 可能具有预测冠状动脉疾病严重程度的能力。